<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708446</url>
  </required_header>
  <id_info>
    <org_study_id>1013</org_study_id>
    <nct_id>NCT02708446</nct_id>
  </id_info>
  <brief_title>A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion</brief_title>
  <official_title>A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>La Rabta Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Republican Institute of RH, Perinatology, and Ob/Gyn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kathmandu Medical College and Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinic No. 2 of Tashkent Medical Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to directly compare repeat doses of sublingual and buccal
      routes of 400 mcg misoprostol following mifepristone for second trimester abortion in order
      to determine if sublingual route confers an advantage with respect to efficacy and median
      time to complete abortion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women 13-21 weeks gestation who give informed consent will be randomized to receive
      buccal or sublingual misoprostol. Participants will take 200mg mifepristone and return to the
      hospital 24 hours later to begin induction with misoprostol. 400mcg misoprostol will be given
      every 3 hours until the expulsion of the fetus and placenta.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful abortion by 24 hours</measure>
    <time_frame>24 hours following the start of misoprostol</time_frame>
    <description>Defined as complete evacuation of uterus at 24 hours following start of misoprostol, using study drugs without recourse to any additional intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of successful abortion by 48 hours</measure>
    <time_frame>48hours following the start of misoprostol</time_frame>
    <description>Defined as complete evacuation of uterus at 48 hours following start of misoprostol, using study drugs without recourse to any additional intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time from first dose of misoprostol to complete expulsion of complete expulsion (provider diagnosis of complete expulsion of fetus and placenta).</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring provision of additional interventions.</measure>
    <time_frame>from first drug dose to complete expulsion as documented on study forms, up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of doses of misoprostol.</measure>
    <time_frame>from first drug dose to complete expulsion as documented on study forms, up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of heavy bleeding, uterine rupture, or infection requiring additional treatment</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scale (1-7) as reported by women on questionnaire</measure>
    <time_frame>from first drug dose to complete expulsion as documented on study forms, up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women's acceptability of the assigned method based on 5 point acceptability scale in questionnaire</measure>
    <time_frame>from first drug dose to complete expulsion as documented on study forms, up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Legally Induced Abortion Without Mention of Complication</condition>
  <arm_group>
    <arm_group_label>Sublingual misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg mifepristone + 400mcg sublingual misoprostol q3h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buccal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg mifepristone + 400mcg buccal misoprostol q3h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>200mg oral mifepristone to both study arms</description>
    <arm_group_label>Sublingual misoprostol</arm_group_label>
    <arm_group_label>Buccal misoprostol</arm_group_label>
    <other_name>miropristone</other_name>
    <other_name>Mifeprex</other_name>
    <other_name>Mifegyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buccal misoprostol</intervention_name>
    <description>doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone</description>
    <arm_group_label>Buccal misoprostol</arm_group_label>
    <other_name>cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual misoprostol</intervention_name>
    <description>doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone</description>
    <arm_group_label>Sublingual misoprostol</arm_group_label>
    <other_name>cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet criteria to obtain abortion

          -  Present with closed cervical os and no vaginal bleeding

          -  Live fetus at time of presentation for service

          -  Have no contraindications to study procedures, according to provider

          -  Be able to consent to procedure, either by reading consent document or by having
             consent document read to her

          -  Be willing to follow study procedures

        Exclusion Criteria:

          -  Known previous transmural uterine incision

          -  Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications
             to the use of mifepristone or misoprostol

          -  Any contraindications to vaginal delivery

          -  Presentation in active labor (defined as moderate to severe contractions every 10
             minutes or less)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>b. Republican Institute of Reproductive Health, Perinatology, Obstetrics and Gynecology (RIRHPOG)</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruzanna Abrahamyan, MD</last_name>
      <email>r_abrahamyan@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Ruzanna Abrahamyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kathmandu Medical College</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chanda Karki, MD</last_name>
      <email>chandakarki26@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chanda Karki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Rabta Maternity Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selma Hajri, MD</last_name>
      <email>selma.hajri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ezzedine Sfar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic No. 2, Tashkent Medical Academy</name>
      <address>
        <city>Tashkent</city>
        <country>Uzbekistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dilfuza Kurbanbekova, MD</last_name>
      <email>wwcuzb@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Nepal</country>
    <country>Tunisia</country>
    <country>Uzbekistan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Second Trimester</keyword>
  <keyword>Abortion</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Sublingual</keyword>
  <keyword>Buccal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

